DNMT3B promoter polymorphisms have been reported to be associated with the risk of immune thrombocytopenic purpura (ITP) and malignant solid tumors, such as colorectal cancer, lung cancer, and breast cancer, albeit to varying degrees [18-22]. The gene discussed is DNMT3B; the disease is autoimmune thrombocytopenic purpura.